Do analysts prefer BIAF or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BIAF or MGRX?

In the previous week, bioAffinity Technologies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.91 beat bioAffinity Technologies' score of 0.66 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BMGL or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BMGL or BIAF?

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A bioAffinity Technologies $6.16M 0.76 -$14.91M -$109.45 N/A

Do analysts prefer BIAF or GXAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BIAF or GXAI?

In the previous week, bioAffinity Technologies had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Gaxos.ai. bioAffinity Technologies' average media sentiment score of 0.66 beat Gaxos.ai's score of 0.37 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AIDX or BIAF?

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor AIDX or BIAF?

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 3 articles in the media. 20/20 Biolabs' average media sentiment score of 0.94 beat bioAffinity Technologies' score of 0.66 indicating that 20/20 Biolabs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 20/20 Biolabs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IVF or BIAF?

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher probable upside, research analysts plainly believe INVO Fertility is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor IVF or BIAF?

In the previous week, INVO Fertility and INVO Fertility both had 3 articles in the media. INVO Fertility's average media sentiment score of 1.02 beat bioAffinity Technologies' score of 0.66 indicating that INVO Fertility is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INVO Fertility 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

bioAffinity Technologies (BIAF) Competitors

$7.83 -0.11 (-1.39%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.83 0.00 (0.00%)

As of 07:01 AM Eastern

Compare

BIAF vs. MGRX, BMGL, GXAI, AIDX, and IVF

Should you buy bioAffinity Technologies stock or one of its competitors? bioAffinity Technologies's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), Gaxos.ai (GXAI), 20/20 Biolabs (AIDX), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does bioAffinity Technologies compare to Mangoceuticals?

bioAffinity Technologies (NASDAQ:BIAF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

bioAffinity Technologies has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A
Mangoceuticals	$460K	21.76	-$20.64M	-$1.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

bioAffinity Technologies has a net margin of -257.30% compared to Mangoceuticals' net margin of -4,794.60%. Mangoceuticals' return on equity of -96.39% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, bioAffinity Technologies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.91 beat bioAffinity Technologies' score of 0.66 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Summary

Mangoceuticals beats bioAffinity Technologies on 8 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, bioAffinity Technologies had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Basel Medical Group. bioAffinity Technologies' average media sentiment score of 0.66 beat Basel Medical Group's score of 0.39 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Basel Medical Group	Neutral
bioAffinity Technologies	Positive

Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, meaning that its stock price is 211% less volatile than the broader market.

1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A

Basel Medical Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Basel Medical Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Summary

Basel Medical Group beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to Gaxos.ai?

bioAffinity Technologies (NASDAQ:BIAF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Gaxos.ai has a net margin of -64.81% compared to bioAffinity Technologies' net margin of -257.30%. Gaxos.ai's return on equity of -38.79% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
Gaxos.ai	-64.81%	-38.79%	-36.99%

bioAffinity Technologies has a beta of -1.11, indicating that its stock price is 211% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, bioAffinity Technologies had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Gaxos.ai. bioAffinity Technologies' average media sentiment score of 0.66 beat Gaxos.ai's score of 0.37 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by company insiders. Comparatively, 3.2% of Gaxos.ai shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gaxos.ai has lower revenue, but higher earnings than bioAffinity Technologies. Gaxos.ai is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Gaxos.ai beats bioAffinity Technologies on 9 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

20/20 Biolabs has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. 20/20 Biolabs' return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 3 articles in the media. 20/20 Biolabs' average media sentiment score of 0.94 beat bioAffinity Technologies' score of 0.66 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20/20 Biolabs has higher earnings, but lower revenue than bioAffinity Technologies. 20/20 Biolabs is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	2.64	-$3.74M	-$0.54	N/A
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of bioAffinity Technologies shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats bioAffinity Technologies on 11 of the 14 factors compared between the two stocks.

How does bioAffinity Technologies compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher probable upside, research analysts plainly believe INVO Fertility is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INVO Fertility has a net margin of -116.29% compared to bioAffinity Technologies' net margin of -257.30%. INVO Fertility's return on equity of -85.54% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-116.29%	-85.54%	-31.05%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

In the previous week, INVO Fertility and INVO Fertility both had 3 articles in the media. INVO Fertility's average media sentiment score of 1.02 beat bioAffinity Technologies' score of 0.66 indicating that INVO Fertility is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INVO Fertility	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

bioAffinity Technologies has lower revenue, but higher earnings than INVO Fertility. bioAffinity Technologies is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84M	0.35	-$25.13M	-$33.83	N/A
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

INVO Fertility has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, meaning that its stock price is 211% less volatile than the broader market.

Summary

INVO Fertility beats bioAffinity Technologies on 12 of the 15 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIAF vs. The Competition

Export

Metric	bioAffinity Technologies	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.14M	$9.75B	$7.31B	$13.29B
Dividend Yield	N/A	2.59%	2.52%	12.57%
P/E Ratio	-0.07	34.16	274.39	25.76
Price / Sales	0.76	4.97	685.29	111.79
Price / Cash	N/A	122.11	77.80	52.76
Price / Book	0.32	5.19	10.44	6.34
Net Income	-$14.91M	$315.70M	$3.49B	$360.00M
7 Day Performance	-16.97%	-1.38%	-0.92%	-0.18%
1 Month Performance	50.87%	-1.40%	-4.22%	-4.09%
1 Year Performance	-84.69%	13.92%	16.40%	5.97%

bioAffinity Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIAF bioAffinity Technologies	0.4474 of 5 stars	$7.83 -1.4%	N/A	-87.8%	$5.14M	$6.16M	N/A	57	Positive News Short Interest Increase Gap Up
MGRX Mangoceuticals	1.272 of 5 stars	$0.43 -4.3%	N/A	-80.9%	$9.72M	$460K	N/A	3
BMGL Basel Medical Group	0.1851 of 5 stars	$4.19 -8.7%	N/A	-82.5%	$7.26M	$8.90M	N/A	70	Short Interest Increase
GXAI Gaxos.ai	0.4745 of 5 stars	$0.58 -4.0%	N/A	-67.9%	$6.49M	$1.93M	N/A	3	Positive News
AIDX 20/20 Biolabs	2.9447 of 5 stars	$0.47 +0.1%	$5.00 +962.7%	N/A	$6M	$2.05M	N/A	14	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

bioAffinity Technologies (BIAF) Competitors

BIAF vs. MGRX, BMGL, GXAI, AIDX, and IVF

How does bioAffinity Technologies compare to Mangoceuticals?

Summary

How does bioAffinity Technologies compare to Basel Medical Group?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Summary

How does bioAffinity Technologies compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

bioAffinity Technologies (BIAF) Competitors

BIAF vs. MGRX, BMGL, GXAI, AIDX, and IVF

How does bioAffinity Technologies compare to Mangoceuticals?

Which has preferable valuation and earnings, BIAF or MGRX?

Do analysts prefer BIAF or MGRX?

Do institutionals and insiders have more ownership in BIAF or MGRX?

Is BIAF or MGRX more profitable?

Does the media prefer BIAF or MGRX?

Which has more risk & volatility, BIAF or MGRX?

Summary

How does bioAffinity Technologies compare to Basel Medical Group?

Does the media prefer BMGL or BIAF?

Which has more volatility & risk, BMGL or BIAF?

Do insiders and institutionals have more ownership in BMGL or BIAF?

Do analysts prefer BMGL or BIAF?

Which has stronger valuation & earnings, BMGL or BIAF?

Is BMGL or BIAF more profitable?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Is BIAF or GXAI more profitable?

Which has more risk and volatility, BIAF or GXAI?

Does the media refer more to BIAF or GXAI?

Do insiders & institutionals have more ownership in BIAF or GXAI?

Which has preferable earnings and valuation, BIAF or GXAI?

Do analysts prefer BIAF or GXAI?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Is AIDX or BIAF more profitable?

Does the media favor AIDX or BIAF?

Which has preferable valuation and earnings, AIDX or BIAF?

Do analysts prefer AIDX or BIAF?

Do institutionals and insiders have more ownership in AIDX or BIAF?

Summary

How does bioAffinity Technologies compare to INVO Fertility?

Do analysts prefer IVF or BIAF?

Is IVF or BIAF more profitable?

Does the media favor IVF or BIAF?

Which has stronger earnings & valuation, IVF or BIAF?

Do institutionals & insiders have more ownership in IVF or BIAF?

Which has more volatility & risk, IVF or BIAF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools